PT - JOURNAL ARTICLE AU - Solomon, Olivia AU - Adams, Cameron AU - Horton, Mary AU - Wong, Marcus P. AU - Meas, Michelle AU - Shao, Xiaorong AU - Fedrigo, Indro AU - Hernandez, Samantha AU - Quach, Hong L. AU - Quach, Diana L. AU - Barcellos, Anna L. AU - Coloma, Josefina AU - Busch, Michael AU - Harris, Eva AU - Barcellos, Lisa F. TI - COVID-19 vaccine antibody response is associated with side-effects, chronic health conditions, and vaccine type in a large Northern California cohort AID - 10.1101/2022.09.30.22280166 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.30.22280166 4099 - http://medrxiv.org/content/early/2022/10/01/2022.09.30.22280166.short 4100 - http://medrxiv.org/content/early/2022/10/01/2022.09.30.22280166.full AB - As vaccines have become available for COVID-19, it is important to understand factors that may impact response. The objective of this study is to describe vaccine response in a well-characterized Northern California cohort, including differences in side-effects and antibody response by vaccine type, sex, and age, as well as describe responses in subjects with pre-existing health conditions that are known risk factors for more severe COVID-19 infection. From July 2020 to March 2021, ∼5,500 adults from the East Bay Area in Northern California were followed as part of a longitudinal cohort study. Comprehensive questionnaire data and biospecimens for COVID-19 antibody testing were collected at multiple time-points. All subjects were at least 18 years of age and members of the East-Bay COVID-19 cohort who answered questionnaires related to vaccination status and side-effects at two time-points. Three vaccines, Moderna (2 doses), Pfizer-BioNTech (2 doses), and Johnson & Johnson (single dose), were examined as exposures. Additionally, pre-existing health conditions were assessed. The main outcomes of interest were anti-SARS-CoV-2 Spike antibody response (measured by S/C ratio in the Ortho VITROS assay) and self-reporting of 11 potential vaccine side effects. When comparing both doses of the Moderna vaccine to respective doses of Pfizer-BioNTech, participants receiving the Moderna vaccine had higher odds of many reported side-effects. The same was true comparing the single-dose Johnson & Johnson vaccine to dose 2 of the Pfizer-BioNTech vaccine. The antibody S/C ratio also increased with each additional side-effect after the second dose. S/C ratios after vaccination were lower in participants aged 65 and older, and higher in females. At all vaccination timepoints, Moderna vaccine recipients had a higher S/C ratio. Individuals who were fully vaccinated with Pfizer-BioNTech had a 72.4% lower S/C ratio compared to those who were fully vaccinated with Moderna. Subjects with asthma, diabetes, and cardiovascular disease all demonstrated more than a 20% decrease in S/C ratio. In support of previous findings, we show that antibody response to the Moderna vaccine is higher than the Pfizer-BioNTech vaccine. We also observed that antibody response was associated with side-effects, and participants with a history of asthma, diabetes, and cardiovascular disease had lower antibody responses. This information is important to consider as further vaccines are recommended.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by grants from Open Philanthropy, Fast Grants, Mercatus Center, the UC Berkeley Innovative Genomics Institute, and the UC Berkeley Center for Population Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of California, Berkeley Committee on Protection of Human Subjects (Protocol #2020-03-13121).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified individual participant data that underlie the results reported in this article (text, tables, figures may be shared for up to 36 months following publication after investigators whose proposed use of the data has been approved by an independent review committee. For individual participant data analysis or meta-analysis, proposals should be directed to Lisa Barcellos (lbarcellos@berkeley.edu) and Lynn Hollyer (lhollyer@berkeley.edu). Requests will be reviewed by an independent review committee and the UC Berkeley Institutional Review Board. Data may be shared upon approval. Data requestors will need to sign a data access agreement.